

# Genetic Approaches Used To Manage Patients with Breast Cancer: Implications for Individualized Therapy and Translational Medicine

Jianqin Wu<sup>1\*</sup>, Jianguo Yuan<sup>2\*</sup>, Guojin Chen<sup>3</sup>, Yujia Li<sup>1</sup>, Shilin Li<sup>1</sup>, Xiaoqiong Duan<sup>1</sup>, Bing Liu<sup>1</sup> and Limin Chen<sup>1,4\*</sup>

<sup>1</sup>Institute of Blood Transfusion (IBT), Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan, 610052, China

<sup>2</sup>Sichuan Mingri Pharmaceutical Research Institute of New Technology, Chengdu, Sichuan 610100, China

<sup>3</sup>Affiliated Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610000, China

<sup>4</sup>Toronto General Research Institute, University of Toronto, Toronto, ON M5G 1L6, Canada

\*Equally contributed to the manuscript

## Introduction

Breast cancer is the cancer that forms in tissues of the breast and it is one of the most common cancers in women. Treatment strategies include surgery, radiation, biological therapy, and supplemental hormone therapy, but the efficacy of these therapies need improving and tumor recurrence is still a problem. In addition, various side effects, such as anemia, toxicity are quite common in breast cancer patients [1-4]. Effective communication with patients is crucial to address concerns and symptoms, and more studies are needed to discover effective strategies to minimize these side effects [2].

Breast cancer is the most common cancer in women both in the developed and developing countries. It is estimated that more than 508 000 women died worldwide in 2011 due to breast cancer (Global Health Estimates, WHO 2013). Although breast cancer is considered to be a disease of the developed world, almost 50% of breast cancer cases and 58% of deaths occur in the developing countries (GLOBOCAN 2008). Incidence rates vary greatly worldwide from 19.3 per 100,000 women in Eastern Africa to 89.7 per 100,000 women in Western Europe. In most of the less developed regions the incidence rates are under 40 per 100,000 (GLOBOCAN 2008). The lowest incidence rates are found in most African countries but the incidence rates are also going up.

It has been shown that the progression of primary and secondary tumors into uncontrolled proliferation plays a vital role in the pathogenesis of breast cancer [5]. Breast cancer in young women is still a big challenge to patients, families and health care providers. Although the diagnosis of breast cancer is much less common in women under the age of 40 years old, it can have a greater influence than in older counterparts, as it tends to be more aggressive and has a poorer prognosis [6-7]. With the development of high throughput screening methods, various genetic approaches were developed to better management of patients with breast cancer, especially in predicting cancer recurrence and chemo-sensitivity.

## Genetic Approaches used to Manage Breast Cancer

Genetic approaches have been successfully used to study many diseases. As for the breast cancer, a lot of host genes as biomarkers have been validated in the prediction of tumor recurrence. In this editorial, we first present the predictive value of 21-gene signature followed by HER2, HOXB13, IL17BR and other host genes reported rarely.

### 21-gene signature

21-gene Recurrence Score (RS) is a gene expression profile assay currently endorsed for use in patients with endocrine-sensitive node-negative breast cancers. The RS has been shown to supplement current 'prognostic' and 'predictive' assessments of relapse risk and chemotherapy benefits, respectively, and lead to significant changes in oncologists' recommendation for adjuvant chemotherapy, with an overall reduction in chemotherapy utilization [8]. Following surgery,

one obvious question is whether a given patient should receive chemotherapy or not. For those patients with low recurrence risk, use of chemotherapy is not only waste of money but also make them suffer from unnecessary side-effects. Genome Health developed a genetic method by examining the gene expression levels of 21-genes from surgery-resected breast cancer tissue to determine the risk of tumor recurrence in order to help doctors make sound decision. From retrospectively study, doctors make therapy decision according to 21-gene recurrence score [9], Furthermore, many patients with intermediate Recurrence Score values switched one therapy to another because chemo hormonal treatment tended to decrease following assay results [10].

### HER2

Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) can lead to breast cancer. But only 15% to 20% patients with breast cancer are HER2 positive [11]. Testing status of HER2 is critical for treatment decision as to whether HER2-targeted therapy should be used. HER2 expression can be tested by Immunohistochemistry (IHC) or *In situ* Hybridization (ISH). In addition to help doctor decide whether anti-HER2 agents should be used or not, patients with HER2 positive may have a lower risk of recurrence [12].

### HOXB13:IL17BR

Homeobox B13 (HOXB13) is a protein encoded by HOXB13 gene while Interleukin-17 receptor B (IL17BR) is encoded by IL17BR gene. The HOXB13/IL17BR ratio index is used as a prognostic biomarker for breast cancer. HOXB13/IL17BR (H/I) and Molecular Grade Index (MGI) have been shown to have predictive value from the retrospective study. Among the patients treated with tamoxifen, more than 50% are low risk and less than 10% have 10 years distant recurrence risk [13]. Tamoxifen can prolong the longer Distant Recurrence-Free Survival (DRFS) of patients with low levels of HOXB13 expression [14]. Another medication such as letrozole treatment can decrease the late recurrence for patients with high H/I [15].

\*Corresponding author: Limin Chen, Toronto General Research Institute, University of Toronto, ONM5G 1L6, Canada, Tel: 86-28-66430656; E-mail: [limin.chen@utoronto.ca](mailto:limin.chen@utoronto.ca)

Received September 27, 2014; Accepted September 29, 2014; Published October 03, 2014

Citation: Wu J, Yuan J, Chen G, Li Y, Li S, et al. (2014) Genetic Approaches Used To Manage Patients with Breast Cancer: Implications for Individualized Therapy and Translational Medicine. J Bioanal Biomed 6: e126. doi:10.4172/1948-593X.1000e126

Copyright: © 2014 Wu J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## 95-gene signature

95-gene classifier has been used as predictor for relapse in breast cancer with high accuracy, and it could separate patients into high-risk and low-risk groups. In estrogen receptor positive(ER+) patients with node negative, 10 years recurrence-free survival rates of low-risk is 93% whereas the counterpart of low-risk is 53% [16].

## Ki-67

Ki-67 is a protein that is associated with cell proliferation, and it is assessed by immunohistochemistry method on formalin-fixed paraffin-embedded blocks. Recurrent patients have higher Ki67 values while overall survival is significantly lower in patients with high Ki67 values [17].

## Future Direction

With traditional therapy, patients usually get adjuvant therapy after surgery for the sake of avoiding the recurrence. Many patients have low-risk of recurrence but they also have to receive such treatment. So the individualized therapy is becoming more and more important in the field of breast cancer treatment in order to recommend whether a given patient should be given chemotherapy following tumor resection. For those patients with low risk of recurrence, sparing chemotherapy can not only save cost but also avoid side effects.

## Financial Support

This study was partially supported by grants from the Sichuan Provincial Science and Technology Department (2013HH0013 to Dr.L Chen and 2013JY0048 to Dr. S Li through the Institute of Blood Transfusion, Chinese Academy of Medical Sciences/Peking Union Medical College, China and 2013SZ0066 to Drs. J Yuan through Sichuan Mingri Pharmaceutical Research Institute of New Technology.

## References

1. Sjoval K, Strombeck K, Lofgren A, Bendahl PO, Gunnars B (2010) "Adjuvant radiotherapy of women with breast cancer information, support and side-effects". *European Journal of Oncology Nursing* 14: 147-153.
2. Connor C, Attai D (2013) "Adjuvant endocrine therapy for the surgeon: options, side effects, and their management." *Annals of Surgical Oncology* 20: 3188-3193.
3. Gianni L, Cole BF, Panzini I, Byrne M, Aebi S, et al. (2008) Anemia during adjuvant non-taxane chemotherapy for early breast cancer: incidence and risk factors from two trials of the International Breast Cancer Study Group. *Supportive Care in Cancer* 16: 67-74.
4. Kado K, Forsyth A, Patel PR, Schwartz JA (2012) "Dietary supplements and natural products in breast cancer trials." *Frontiers in Bioscience Elite* 4: 546-567.
5. Marvibaigi M, Supriyanto E, Amini N (2014) Preclinical and Clinical Effects of Mistletoe against Breast Cancer Mohsen. *BioMed Research International*.
6. Han W, Kim SW, Park IA, Kuk JC, Seung KO, et al. (2004) Young age: an independent risk factor for disease-free survival in women with operable breast cancer. *BMC Cancer* 4: 82.
7. Brennan M, French J, Houssami N (2005) Breast cancer in young women. *Aust Fam Physician* 34: 851-855.
8. Lamond NW, Younis T, Skedgel C (2013) Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer. *Expert Review of Pharmacoeconomics and Outcomes Research* 13: 243-250.
9. Clara Chen, Rahul Dhanda, Wan-Yu Tseng (2013) Evaluating Use Characteristics for the Oncotype Dx 21-Gene Recurrence Score and Concordance With Chemotherapy Use in Early-Stage Breast Cancer. *Health Care Delivery* 4: 182-192.
10. Hideko, Yamauchi, Chizuko, Nakagawa, Takie H, Hell S, et al. (2014) Prospective Study of the Effect of the 21-Gene Assay on Adjuvant Clinical Decision-Making in Japanese Women With Estrogen Receptor-Positive, Node-Negative, and Node-Positive Breast Cancer. *Clinical Breast Cancer* 14: 191-197.
11. Antonio C, Wolff M, Elizabeth H, Hammond, Hayes DF, et al. (2013) Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. *Journal Of Clinical Oncology* 13: 3997-4014.
12. Guarneri V, Dieci MV, Omarani C, Ficarra G, Conte PF, et al. (2013) Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. *Annals of Oncology* (24): 2990-2994.
13. Jerevall PL, XJ Ma, Li H, Kesty NC, Skoog L, et al. (2011) Prognostic utility of HOXB13: IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial[J]. *British Journal of Cancer* 104: 1762-1769.
14. Jerevall PL, Olle S, Jansson A, Tommy F, Skoog L, et al. (2010) Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer. *Breast Cancer Research* 12: 53.
15. Dennis C, SgROI Erin, Carney, Binns SN, Porter P, et al. (2013) Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. *Journal of the National Cancer Institute* 105: 1036-1042.
16. Yasuto, Naoi, Kazuki, Kishi, Baba Y, et al. (2011) Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients. *Breast Cancer Research Treatment* 128: 633-641.
17. Heba M, Elzawahry, Magdy M, Saber, Ismail YM, et al. (2013) Role of Ki67 in predicting resistance to adjuvant tamoxifen in postmenopausal breast cancer patients. *Journal of the Egyptian National Cancer Institute* 25: 181-191.